BeBetter Med Inc.

The company was founded by Professor Qian Changgeng, a special expert on the “National Major Talent Project”, and his team in Guangzhou in 2012. It is a CNI Biomedicine Index enterprise guided by clinical value and focusing on independent research and development of innovative drugs. The company adheres to the vision of “committed to innovation and the pursuit of better”, insists on independent innovation, and is committed to developing safe and effective innovative drugs with independent global intellectual property rights. The company focuses on major diseases such as tumors, autoimmune diseases, and metabolic diseases. Relying on a core technology platform developed independently, the company continues to develop first-in-class drugs (first-in-class) that are urgently needed clinically and innovative drugs that do not meet clinical needs. As of the date of signing of this prospectus, the company's R&D pipeline has 6 independently developed innovative drug core products that are in the clinical trial stage or are about to begin clinical trials. The company's shares were listed on the Star of the Shanghai Stock Exchange on October 28, 2025.